Explore published research on seniors, including study methods and limitations.
California designed a four-protocol statewide program to study THC dosing for cancer nausea across ages, involving over 200 investigators and including children and elderly patients.
Among nearly 30,000 adults over 50, marijuana-only users had 1.5x higher odds of depression vs. non-users, though they fared better than users of other illicit drugs.
Among HIV-positive adults over 50 in care, marijuana was the most commonly used illicit drug (32.6%), and more than a third of users had never received substance use treatment.
Twelve elderly people accidentally ate marijuana cookies at a hemp food workshop, sending two to intensive care, though all recovered fully.
Cannabis use among Americans over 50 surged between 2006-2013, with a 250% increase among those 65+, while most older users perceived little to no risk.
Dispensary study of 217 patients finding younger medical cannabis users consume more and show more problematic use than older users, with early initiation as a key risk factor.
Essay examining rising cannabis use among Americans 65+, arguing cannabis may be a viable alternative to opioids for pain but calling for more research on this understudied population.
Review of herbal medicine use in elderly IBD patients identifies cannabis among many supplements with potential drug-herb interactions, emphasizing the need for provider awareness.
Review examines the growing challenge of accommodating medical marijuana in long-term care, where 30-state legalization collides with federal prohibition and complex regulatory requirements.
A study of 5,452 cannabinoid prescription users in Manitoba found only 18% continued use at one year, with median duration of 31 days varying by diagnosis and medication type.
Focus groups with 136 Colorado adults over 60 found older adults want cannabis education from providers but stigma and lack of research prevent meaningful conversations about use.
Nine of 11 cannabinoids protected neurons in an Alzheimer's drug screening model, removed amyloid, and worked through both receptor-dependent and independent mechanisms.
Survey of 2,905 users found older adults and medical users experience fewer adverse effects, but medical users report more withdrawal symptoms. Only 17% thought cannabis is addictive.
Study of 1,285 adults aged 40+ found heavy marijuana smoking more than doubled COPD risk and accelerated lung decline beyond tobacco alone.
Review found cannabinoids may help older adults with pain and nausea, with moderate risks, but few studies have specifically included elderly patients.
Mouse study found cannabinoids were more potent in aged mice than young adults, with stronger pain relief and movement suppression, suggesting elderly users may need lower doses.
A Cochrane review of four trials (126 participants) found very low to low certainty evidence that cannabinoids have little or no meaningful effect on cognition or behavioral symptoms in dementia. The evidence base is too small for conclusions.
Rural Australian healthcare providers were generally positive about medical cannabis for older patients but identified stigma, complex regulations, limited rural access, and restrictive driving laws as major barriers to prescribing.
A systematic review of five trials found the synthetic cannabinoid nabilone may reduce agitation in dementia, but natural THC showed no benefit. No studies have tested cannabinoids for cognitive decline in dementia.
Women over 50 comprised 57% of cannabis poison control cases and were nearly twice as likely as men to call about therapeutic errors rather than misuse, often involving edibles and other non-plant cannabis products.
Cannabis poison control cases among adults over 50 increased 18-fold from 2009 to 2019, with non-plant products surging 51-fold. Synthetic cannabinoid products carried twice the risk of serious medical outcomes.
National survey of 18,794 older adults found perceived risk of regular cannabis use dropped nearly 19% between 2015-2019, with the steepest declines among those with chronic diseases.
National survey of 4,069 veterans found 11.9% cannabis use overall, rising to 24-30% among those with psychiatric conditions, with depression independently tripling CUD risk.
Small study of 16 older adults found chronic cannabis users had higher fall risk, worse balance, and slower walking speed than matched non-users, though cognitive function was similar.
Survey of 568 adults 65+ found 15% used cannabis, with most starting after 60 for medical purposes (mainly pain), yet only 41% told their healthcare provider.
Marijuana improved spatial learning in female rats, but combining it with estrogen in older rats produced negative cognitive effects through the GPR30 receptor.
A study of 44,007 adults aged 50+ found cannabis users had more ER visits but not more hospitalizations, with medical-only users driving the increased ER utilization.
A review argues that combining CBD and THC may treat Alzheimer's more effectively than either alone, based on preclinical evidence of complementary neuroprotective mechanisms.
Preclinical evidence for cannabinoids in Parkinson's and Alzheimer's is promising, but older adults are using them off-label despite almost no clinical trial data.
A survey of 342 terminally ill medical cannabis patients found very low hospice enrollment, suggesting cannabis may serve as an alternative rather than complement to end-of-life care.
Among 297,620 veterans on opioids, cannabis use did not reduce mortality. In adults 65+ on long-term opioids, cannabis was associated with 55% higher 90-day mortality.
Two years of THC/CBD treatment in 19 elderly dementia patients showed good safety and reduced behavioral symptoms, but without a control group, the benefits remain unproven.
Matched cohort in Hawaii found older cannabis users (50+) had higher rates of heart disease, stroke, chronic pain, MI, and used more healthcare services over two years compared to non-using controls.
Menopausal mice treated with CBD for 18 weeks had improved blood sugar, bone density, and energy expenditure, along with increased gut Lactobacillus.
Scoping review of animal studies found cannabinoid exposure during brain development (prenatal, adolescent) caused lasting cognitive harm, while exposure in old age showed potential cognitive benefits.
Interviews with 32 older veterans found they use medical cannabis to replace opioids and benzodiazepines, but face inconsistent VA policies and minimal physician guidance.
Mouse study found CBD protected against Alzheimer's-related cognitive deficits by modulating microglial activity and inflammatory gene expression.
Study of 2,095 older drivers found cannabis users had 58% more traffic stops but no significant increase in crashes, possibly because they rarely drove after use.
Geriatrics clinic survey found elderly cannabis users treating sleep problems prefer THC over CBD, use daily, and take it right before bed — often without clinician guidance.
A chart review of elderly cancer patients found no significant improvement in pain, nausea, appetite, insomnia, or anxiety scores after starting medical cannabis.
Scoping review finds growing cannabis use among older adults but limited evidence on age-specific safety, efficacy, and drug interaction concerns.
Mixed-methods study found many older California adults hesitated to disclose medical cannabis use to doctors due to stigma and fear of judgment.
Isolated heart mitochondria from old rats showed nearly double the damage from THC compared to young rats, with alcohol worsening the effect and increasing harmful reactive oxygen species production.
BRFSS survey of 4,744 adults aged 45+ found non-medical cannabis use associated with 96% lower odds of self-reported cognitive decline, though the extreme effect size likely reflects selection bias rather than a true protective effect.
Population study of 910 adults 65+ found 20% had used marijuana and 5% used recently — current users showed more depression, anxiety, and functional impairment.
An EMA study of 106 older adults found medical cannabis reduced pain, mood, nausea, and trauma symptoms throughout the day, but the use-then-relief pattern was linked to developing cannabis use disorder symptoms.
A survey of 575 cannabis-educated providers found most did not routinely ask older adult patients about medical cannabis, significantly less often than they asked about alcohol or tobacco.
A longitudinal survey of older US veterans in a medical cannabis program found improved pain and sleep outcomes, with 44% of opioid co-users stopping opioids at follow-up.
Lab and animal studies show CBD may protect against Alzheimer's-related neurodegeneration, but no controlled human trials have been conducted.
Lab tests showed THC/THCA-dominant cannabis extracts protected brain cells from Alzheimer's-related amyloid-beta toxicity, but not by preventing plaque formation.
Ninety-day cannabinoid treatment in Alzheimer's model mice reduced amyloid plaque deposits, improved memory, and decreased brain inflammation markers.
Meta-analysis of 58 RCTs in adults 50+ found cannabinoid medicines increase common side effects dose-dependently but do not significantly increase serious adverse events, withdrawals, or deaths.
Study of 12,599 Ontario seniors found those taking both medical cannabis and warfarin had higher bleeding rates — the first population-level evidence of clinical harm from cannabis drug interactions.
19 U.S. states list Alzheimer's as a medical cannabis qualifying condition, but <1% of certifications are for AD, and clinical evidence supporting cannabis for dementia agitation is sparse.
Longest cannabinoid trial in Alzheimer's: 26 weeks of very low-dose THC-CBD extract showed significantly higher cognitive scores vs placebo.
A crossover study of 31 adults aged 65-78 found smoking cannabis impaired trail-making performance but not most other cognitive tests, with blood THC levels poorly predicting cognitive effects in this age group.
Chronic CBD treatment increased brain copper in healthy female mice but not in Alzheimer's model mice, disrupting the coordinated regulation of metals across brain regions in the disease model, suggesting CBD's brain effects differ between healthy and diseased states.
CBD selectively induced beneficial cell death in amyloid-beta-expressing cells while causing side effects in healthy cells, with FAAH involvement helping to rescue dysfunction in amyloid-expressing worm models, revealing context-dependent effects.
Older chronic pain patients starting medical cannabis were 54% more likely to begin long-term opioids the following year.
UK Biobank analysis of 25,000+ people found cannabis users had brain network patterns resembling younger brains and better cognitive performance.
UK Biobank data from adults aged 40-70 found lifetime cannabis use associated with larger brain volumes in key regions and better cognitive performance.
Among 4,285 veterans with heart disease, cannabis smoking was linked to higher rates of heart attack, stroke, and cardiovascular death—though confounders remain.
A survey of 4,134 daily cannabis users found older adults used less potent products, but their risk of cannabis use disorder per milligram of THC was similar to younger users.
Analysis of millions of VHA patients from 2005-2022 found cannabis legalization was associated with small increases in opioid use disorder, with the largest effects in older adults with chronic pain.
Review finds CBD targets multiple Alzheimer's pathways in preclinical studies, with computer modeling revealing potential gene targets for future research.
Aging mice given oral CBD for 7 months showed reduced brain inflammation and improved cognitive function across multiple brain region-specific tasks.
Parkinson's RCT finds 26 mg/day CBD was safe but showed limited cognitive benefit beyond naming scores, with the low dose potentially below the therapeutic threshold.
Alzheimer's mice treated with a synthetic cannabinoid for 42 days showed improved memory and motor function plus reduced brain plaques and inflammation.
Low-dose cannabinoid treatment prevented spatial memory loss in rats by indirectly boosting the cholinergic system through cannabinoid receptor activation in cortical regions.
Among 540 older adults across the dementia spectrum, moderate cannabis use was not associated with worse cognitive test performance—though problem use may differ.
A narrative review of cannabis effects across the lifespan found that prenatal and adolescent exposure carries the highest neurological risk, while cannabis use among older adults is rising fastest with the least risk awareness.
An Ontario study of 6.1 million adults over 45 found that those with emergency visits for cannabis use had 1.72x higher dementia risk than the general population, though lower risk than those with alcohol-related visits.
A systematic review of 18 studies found preclinical promise for cannabinoids in supporting healthy aging, but noted that human evidence remains too sparse to draw definitive conclusions.
A triple-blind crossover trial of 17 older adults with poor appetite found that a THC/CBD mouth spray did not increase caloric intake compared to placebo, though it was well tolerated.
A synthetic cannabinoid rescued memory deficits, reduced brain inflammation, and restored glucose metabolism in Alzheimer's mice without increasing anxiety.
PET imaging in Alzheimer's mice showed the brain's cannabinoid system changes early in disease, with sex-dependent patterns that could guide treatment approaches.
Small RCT found CBD 300 mg/day significantly reduced behavioral symptoms of vascular dementia after 4 weeks without cognitive or functional side effects.
Low-dose THC given daily for three weeks improved wound healing in old mice by coordinating immune cell responses and reducing inflammation at the wound site.
JAMA study of 4,503 older veterans found 10.3% used cannabis monthly, with over a third of users screening positive for cannabis use disorder. Smoking was linked to 3.5x higher CUD odds than edibles.
Focus groups with 72 Canadians aged 60+ found older adults use cannabis for pain and mental health but lack guidance from healthcare providers about risks and drug interactions.
A geriatric primary care clinic embedded a medical cannabis program—providing 144 supervised visits to older adults navigating cannabis use with complex medical needs.
Among 353 older adults with chronic pain, the small minority using cannabis had more pain interference and depression over time—though the tiny sample size limits conclusions.
Multi-state analysis of social equity programs in legal cannabis found wide variation in design and outcomes, with persistent gaps between policy goals and actual representation.
Only 19% of older cannabis users discussed use with clinicians; Hispanic/Latine adults least likely to be screened.
Older adults had lower baseline endocannabinoid levels but showed larger increases after cannabis use than younger adults.
Review argues that older adults may be more impaired by cannabis while driving due to age-related changes in metabolism, cognition, and the endocannabinoid system.
Review explored how age-related endocannabinoid system changes and chronic inflammation ('inflammaging') create a rationale for cannabinoid pain therapy in older adults, though clinical evidence is limited.
Multicenter RCT finds dronabinol (THC) safely and effectively reduces Alzheimer's agitation over 3 weeks with a medium effect size and no cognitive decline.
CBD:THC (99:1) mixture enhanced microglial clearance of Alzheimer's plaques in mice but also worsened anxiety and depression behaviors, highlighting the therapeutic trade-off.
Pharmacokinetic study of oromucosal THC in 20 older patients with poor appetite found extremely large absorption variability (40-152% CV), with no patient characteristics predicting individual response.
Review highlights that older adults are increasingly using cannabis for pain and insomnia, but research on cardiovascular risks, cognitive effects, and neurodegeneration in aging populations is just beginning.
NHANES analysis of nearly 6,000 middle-aged adults found frequent cannabis use linked to significantly lower Klotho, an aging biomarker, with a dose-dependent relationship.
NHANES analysis of nearly 13,000 adults found current marijuana users showed accelerated biological aging, with cadmium from smoke explaining about 8-16% of the effect.